• Hello Guest,
    We are experiencing difficulties in sending emails. It related to our platform and how it handles the requests. We are working on it. For now, we are using manual methods in sending emails. Please check your SPAM folder as well. Please let me know if you're still experiencing any issue? Use the Contact US at the bottom of the page to reach out.

    Best regards,
    VETeLiB Admin

Masters Pharmacokinetics of flaxseed lignans in the rat


Jul 1, 2012
Reaction score
Iraq Professor at Vet School
Valeriya Kotlyarova
Secoisolariciresinol diglucoside (SDG) is the principal lignan of the flaxseed. In the human body it is metabolized to secoisolariciresinol (SECO) and then to enterodiol (ED) and enterolactone (EL). It has been shown that these compounds help to prevent the development of some hormone dependent diseases (breast, prostate cancers) and type II diabetes. Given numerous health benefits, evaluation of lignan pharmacokinetics is critical to understanding their pharmacology. This research aimed to assess SECO pharmacokinetic parameters in the rat.
The first objective was to isolate pure SDG and SECO sufficient for a pharmacokinetic study. SDG (≥95% purity) was obtained from SDG (40% purity) by preparative HPLC. SECO (≥95% purity) was produced from SDG by acid hydrolysis.
The second objective was to develop and validate an HPLC method with fluorescence detection suitable for pharmacokinetic applications. The method is specific for SECO, ED, and EL quantification in rat serum. Separation is achieved with a C18 reversed-phase column under gradient mobile phase conditions, consisting of water and acetonitrile buffered with 0.1% formic acid. Analytes are extracted with diethyl ether and 7-hydroxycoumarin serves as an internal standard. Calibration curves are linear from 0.01 to 10 μg/mL for SECO/ED and 0.05-10 μg/mL for EL. Accuracy and precision are within FDA specified limits.
The third objective was to assess the pharmacokinetics of SECO after a single intravenous (20mg/kg) and oral bolus (40 mg/kg) administration in rat. SECO pharmacokinetic parameters were assessed based on a 12-hour study in Wistar male rats (n=12). The results were reported as mean ± SD: systemic clearance 3.1±1.0 L/h, volume of distribution 17.7±8.3 L, half-life 4.7±3.6 h, and oral bioavailability 26 %. SECO undergoes enterohepatic recirculation and exhibits two-compartment model characteristics with large volume of distribution and low oral bioavailability.

[thanks-thanks]pdf,503KB, http://www.mediafire.com/view/?kg7wpsb4bxjsosb[/thanks-thanks]
Last edited: